QNCX

Quince Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on developing treatments for debilitating and rare diseases with unmet medical needs. Headquartered in Fort Worth, Texas, the company concentrates its efforts on neurologic and orphan mitochondrial diseases. Quince's lead product candidate, KL1333, is a novel compound designed to enhance mitochondrial function and is currently in clinical development for primary mitochondrial diseases, including Leigh syndrome and other mitochondrial encephalopathies. The company emerged from a strategic transformation when Cortexyme, Inc. pivoted from Alzheimer's disease research to focus on mitochondrial disorders, subsequently rebranding as Quince Therapeutics in 2023. This shift followed the discontinuation of atuzaginstat, its previous lead Alzheimer's candidate, after Phase 2/3 trial results. Quince maintains strategic partnerships and collaboration agreements to advance its pipeline and operates as a lean organization typical of early-stage biotechnology firms. The company conducts its clinical trials across multiple sites and works with academic medical centers specializing in mitochondrial disorders. As of its latest reports, Quince remains pre-revenue and focuses its resources on advancing KL1333 through clinical trials while exploring additional opportunities in the rare disease space. The company trades publicly on the Nasdaq exchange under the ticker symbol QNCX.